linsitinib
linsitinib
An imidazopyrazine that is imidazo[1,5-<em>a</em>]pyrazine substituted by 2-phenylquinolin-7-yl, <i>cis</i>-3-hydroxy-3-methylcyclobutyl, and amino groups at positions 1, 3, and 8, respectively. It is dual inhibitor of the IGF-1 receptor and insulin receptor (IC<small><sub>50</sub></small> = 35 and 75 nM, respectively) that was previously in clinical development for the treatment of cancer and thyroid eye disease.